Elizabeth C James

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Andrew R. Clamp, Elizabeth C James, Iain A. McNeish et al. · The Lancet · 2019 · 223 citations · Full text

Medicine, Gynecology, Oncology +14

Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

Robert D. Morgan, Iain A. McNeish, Adrian Cook et al. · The Lancet Oncology · 2020 · 63 citations · Full text

Medicine, Gynecology, Oncology +12

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

Johnathan Joffe, Fay Cafferty, Laura Murphy et al. · Journal of Clinical Oncology · 2022 · 59 citations · Full text

Medicine, Oncology, Radiology +17

ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis

A. Clamp, Iain A. McNeish, Andrew Dean et al. · Annals of Oncology · 2017 · 51 citations

Medicine, Gynecology, Oncology +13

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

Andrew R. Clamp, Elizabeth C James, Iain A. McNeish et al. · The Lancet Oncology · 2022 · 45 citations · Full text

Medicine, Gynecology, Oncology +14